BIO-PATH HOLDINGS, INC. Files Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT

TL;DR

<b>BIO-PATH HOLDINGS, INC. has filed an amendment to its S-1 registration statement, indicating ongoing efforts to offer securities.</b>

AI Summary

BIO-PATH HOLDINGS INC (BPTH) filed a Amended IPO Registration (S-1/A) with the SEC on January 23, 2024. BIO-PATH HOLDINGS, INC. filed an amendment (No. 1) to its Form S-1 Registration Statement on January 23, 2024. The filing is under the Securities Act of 1933, with Registration No. 333-276239. The company's principal executive offices are located at 4710 Bellaire Boulevard, Suite 210, Bellaire, Texas 77401. The IRS Employer Identification Number is 87-0652870. The company was formerly known as OGDEN GOLF CO CORP, with a name change date of 2001-02-05.

Why It Matters

For investors and stakeholders tracking BIO-PATH HOLDINGS INC, this filing contains several important signals. This S-1/A filing signifies that Bio-Path Holdings is actively pursuing a public offering of its securities, which could lead to new investment opportunities and increased liquidity. The amendment suggests updates or clarifications to the initial registration statement, potentially addressing SEC comments or providing updated financial and business information relevant to potential investors.

Risk Assessment

Risk Level: low — BIO-PATH HOLDINGS INC shows low risk based on this filing. The filing is an S-1/A, which is an amendment to a registration statement, indicating a procedural step rather than a significant event with immediate financial implications.

Analyst Insight

Monitor for the effectiveness of the registration statement and any subsequent prospectus filings for details on the securities offering and valuation.

Key Numbers

• 333-276239 — Registration Number (Securities Act of 1933)
• 87-0652870 — I.R.S. Employer Identification Number (Company identifier)
• 20010205 — Date of Name Change (Former company name)

Key Players & Entities

• BIO-PATH HOLDINGS, INC. (company) — Registrant name
• Peter H. Nielsen (person) — President and Chief Executive Officer
• William R. Rohrlich, II (person) — Copies To
• Winstead PC (company) — Legal counsel
• M. Ali Panjwani (person) — Copies To
• Pryor Cashman LLP (company) — Legal counsel
• OGDEN GOLF CO CORP (company) — Former company name

Forward-Looking Statements

• BIO-PATH HOLDINGS INC will initiate a public offering of securities within the next 6-12 months. (BIO-PATH HOLDINGS INC) — medium confidence, target: 2025-01-23
• The stock price of BIO-PATH HOLDINGS INC will experience increased volatility around the announcement of any future offering. (BIO-PATH HOLDINGS INC) — high confidence, target: 2025-01-23

FAQ

Industry Context

The filing pertains to the pharmaceutical preparations industry (SIC Code 2834), indicating the company operates within the life sciences sector.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the initial offering and registration of securities in the United States.

What Investors Should Do

1. Review the full S-1/A filing for details on the proposed securities offering.
2. Track future SEC filings from BIO-PATH HOLDINGS, INC. for updates on the registration statement's effectiveness and offering details.
3. Research the company's business operations and financial health to assess investment potential.

Key Dates

• 2024-01-23: Filing Date — Amendment No. 1 to Form S-1 Registration Statement
• 2001-02-05: Name Change — From OGDEN GOLF CO CORP to BIO-PATH HOLDINGS, INC.

Year-Over-Year Comparison

This is an amendment (S-1/A) to a previous filing, indicating updates or corrections to the initial registration statement.

Key Financial Figures

• $0.001 — 1 shares of our common stock, par value $0.001 per share, together with warrants to pu
• $0.41 — sumed combined public offering price of $0.41 per share and one Common Warrant to pur
• $1.00 — e did not meet the minimum bid price of $1.00 per share required for continued listin

Filing Documents

• tm2331778-3_s1a.htm (S-1/A) — 634KB
• tm2331778d4_ex4-21.htm (EX-4.21) — 93KB
• tm2331778d4_ex4-22.htm (EX-4.22) — 98KB
• tm2331778d4_ex4-23.htm (EX-4.23) — 101KB
• tm2331778d4_ex5-1.htm (EX-5.1) — 15KB
• tm2331778d4_ex10-39.htm (EX-10.39) — 87KB
• tm2331778d4_ex10-40.htm (EX-10.40) — 177KB
• tm2331778d4_ex23-1.htm (EX-23.1) — 3KB
• tm2331778d4_ex-filingfees.htm (EX-FILING FEES) — 48KB
• lg_biopathholdings-4clr.jpg (GRAPHIC) — 42KB
• tm2331778d4_ex5-1img01.jpg (GRAPHIC) — 20KB
• tm2331778d4_ex5-1img02.jpg (GRAPHIC) — 4KB
• 0001104659-24-005912.txt (&nbsp;) — 1348KB

RISK FACTORS

RISK FACTORS 7 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 11

USE OF PROCEEDS

USE OF PROCEEDS 13

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 16

DESCRIPTION OF SECURITIES WE ARE OFFERING

DESCRIPTION OF SECURITIES WE ARE OFFERING 18

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 21 PLAN OF DISTRIBUTION 30 LEGAL MATTERS 36 EXPERTS 36 WHERE YOU CAN FIND MORE INFORMATION 36 INFORMATION INCORPORATED BY REFERENCE 36 i TABLE OF CONTENTS PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or in documents incorporated by reference. This summary does not contain all of the information that you should consider before making an investment decision. This prospectus includes or incorporates by reference information about this offering, our business and our financial and operating data. You should carefully read the entire prospectus, including under the sections titled "Risk Factors" included herein, and the documents incorporated by reference into this prospectus, before making an investment decision. Unless the context requires otherwise, references in this prospectus to "we," "our," "us," "the Company" and "Bio-Path" refer to Bio-Path Holdings, Inc. and its wholly-owned subsidiary. Bio-Path Holdings, Inc.'s wholly-owned subsidiary, Bio-Path, Inc., is sometimes referred to herein as "Bio-Path Subsidiary." Our Company We are a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. Our drug delivery and antisense technology, called DNAbilize , is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the body's enzymes when circulating in vivo , incorporated inside of a lipid bilayer having neutral charge. We believe this combination allows for high efficiency loading of antisense DNA into non-toxic, cell-membrane-like structures for delivery of the antisense drug substance into cells. In vivo , the DNAbilize delivered antisense drug substances are systemically distri

View Full Filing

View this S-1/A filing on SEC EDGAR